# Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

> **NCT06596915** · PHASE1 · RECRUITING · sponsor: **Shandong Boan Biotechnology Co., Ltd** · enrollment: 167 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Pancreatic Adenocarcinoma
- Breast Cancer
- Melanoma

## Interventions

- **DRUG:** BA1302

## Key facts

- **NCT ID:** NCT06596915
- **Lead sponsor:** Shandong Boan Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-11
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-30
- **Target enrollment:** 167 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06596915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06596915, "Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06596915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*